Tenaya Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Tenaya Therapeutics, Inc. filed this Form 8-K on May 31, 2024, reporting results of its annual meeting of stockholders held on May 30, 2024. The filing concerns corporate governance matters and does not report quarterly or annual financial results.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating metrics. No clear financial values are reported.
Material Changes Versus the Prior Comparable Period
- Class III director nominees Faraz Ali, M.B.A., June Lee, M.D., and Deepak Srivastava, M.D. were elected to serve until the 2027 annual meeting and until their successors are elected and qualified, subject to earlier resignation or removal.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, business outlook, management commentary, contingencies, or unusual financial items. It reports broker non-votes in the director elections but none for the auditor-ratification proposal.
Voting Results
| Proposal | For | Against | Withheld/Abstain | Broker Non-Votes | Outcome |
|---|---|---|---|---|---|
| Election of Faraz Ali | 60,262,398 | — | 157,949 withheld | 10,386,279 | Elected |
| Election of June Lee | 60,205,014 | — | 215,333 withheld | 10,386,279 | Elected |
| Election of Deepak Srivastava | 53,643,731 | — | 6,776,616 withheld | 10,386,279 | Elected |
| Ratification of Deloitte & Touche LLP | 70,778,448 | 16,045 | 12,133 abstain | 0 | Ratified |
Important Facts to Verify
- Confirm the elected directors’ continued service and term through the 2027 annual meeting, subject to earlier resignation or removal.
- Confirm Deloitte & Touche LLP remains the independent registered public accounting firm for the year ending December 31, 2024.
- Review subsequent filings for any changes to the board, auditor, capital position, liquidity, or clinical-program outlook, none of which are addressed in this 8-K.